Copanlisib with Ibrutinib for Patients with Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
The purpose of this study is to test the safety of combined use of the study drugs, copanlisib and ibrutinib, in people with PCNSL.
Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
DRUG: Ibrutinib|DRUG: Copanlisib
maximum tolerated dose (MTD) (phase Ib), The "3+3" design will be applied in the phase Ib portion of the trial., 1 year|overall response rate (ORR) (phase II), To explore the therapeutic efficacy measured by overall response rate (ORR) of Copanlisib in combination with Ibrutinib in patients with refractory/relapsed PCNSL or newly diagnosed PCNSL not able to tolerate standard chemotherapy (phase II)This study will use the modified International Primary CNS Lymphoma Collaborative Group (IPCG)12., 1 year
adverse events in terms of incidence and severity (phase Ib and II), adverse events at each visit with the NCI CTCAE v4.03 used as a guide for the grading of severity., 2 years|progression free survival (PFS) (phase II), Progression-free survival (PFS) is defined as the time from the date of treatment start to the date of the first documented PD or death due to any cause., 2 years|duration of response (DOR) (phase II), Duration of response is defined as the time from the date of first occurrence of CR or PR to the date of the first documented PD or death due to any cause., 2 years|overall survival (OS) (phase II), Overall survival time (OS) is defined as the time from treatment start to the date of death due to any cause., 2 years|To evaluate cerebral spinal fluid (CSF) pharmacokinetics of Copanlisib and Ibrutinib and correlate with plasma pharmacokinetics (phase Ib), 2 years
The purpose of this study is to test the safety of combined use of the study drugs, copanlisib and ibrutinib, in people with PCNSL.